phenyl 2-(2-pyridyl)ethyl ether | 261360-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: phenyl 2-(2-pyridyl)ethyl ether
• 英文别名: 2-(2-Phenoxyethyl)pyridine
• CAS: 261360-86-5
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: HDCZPCKNIMCERD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  phenyl 2-(2-pyridyl)ethyl ether 在 氢溴酸 、 potassium carbonate 、 caesium carbonate 、 potassium iodide 作用下， 反应 1.0h， 生成 2,3,4,9-tetrahydro-2-[2-(2-pyridinyl)ethyl]-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Psychotropic agents: synthesis and antipsychotic activity of substituted .beta.-carbolines

  摘要：

  A series of novel substituted beta-carbolines was synthesized and tested for potential antipsychotic activity. Several compounds displayed moderate antipsychotic activity in vitro and in vivo as determined by relevant receptor binding assays and behavioral tests. The effect of substituents on antipsychotic activity was examined. The beta-carbolines 10 and 19 containing 2-(2-pyridinyl)ethyl and 2-(2-quinolinyl)ethyl side chains were the most potent analogues, blocking discrete trial conditioned avoidance responding in rats with AB50's of 23 and 10 mg/kg, respectively. Both showed moderate activity at the D2 receptor sites, but they lacked oral activity. In contrast, the beta-carboline 13 containing the 4-(4-pyridinyl)butyl side chain exhibited oral activity in the discrete trial conditioned avoidance screen with an AB50 of 31 mg/kg. Most compounds did not antagonize apomorphine-induced stereotyped behavior, which is indicative of low potential for extrapyramidal side effect (EPS) liability.

  DOI：

  10.1021/jm00389a022
• 作为产物：
  描述：

  碳酸甲丙酯 、 2-bromomethoxybenzene 在 氨 、 sodium 作用下， 生成 phenyl 2-(2-pyridyl)ethyl ether
  参考文献：
  名称：

  Psychotropic agents: synthesis and antipsychotic activity of substituted .beta.-carbolines

  摘要：

  A series of novel substituted beta-carbolines was synthesized and tested for potential antipsychotic activity. Several compounds displayed moderate antipsychotic activity in vitro and in vivo as determined by relevant receptor binding assays and behavioral tests. The effect of substituents on antipsychotic activity was examined. The beta-carbolines 10 and 19 containing 2-(2-pyridinyl)ethyl and 2-(2-quinolinyl)ethyl side chains were the most potent analogues, blocking discrete trial conditioned avoidance responding in rats with AB50's of 23 and 10 mg/kg, respectively. Both showed moderate activity at the D2 receptor sites, but they lacked oral activity. In contrast, the beta-carboline 13 containing the 4-(4-pyridinyl)butyl side chain exhibited oral activity in the discrete trial conditioned avoidance screen with an AB50 of 31 mg/kg. Most compounds did not antagonize apomorphine-induced stereotyped behavior, which is indicative of low potential for extrapyramidal side effect (EPS) liability.

  DOI：

  10.1021/jm00389a022

文献信息

• Intramolecular Assistance of Electron Transfer from Heteroatom Compounds. Electrochemical Oxidation of 2-(2-Pyridyl)ethyl-Substituted Ethers, Sulfides, and Selenides
  作者：Mitsuru Watanabe、Seiji Suga、Jun-ichi Yoshida

  DOI：10.1246/bcsj.73.243

  日期：2000.1

  Organoheteroatom compounds having a 2-(2-pyridyl)ethyl group were synthesized and their oxidation potentials were determined by rotating disk electrode voltammetry. The oxidation potentials were found to be less positive than those of the corresponding compounds having a phenyl group in place of the pyridyl group. The dynamic coordination of the pyridyl group to the heteroatom, which stabilizes the

  合成了具有 2-(2-吡啶基)乙基的有机杂原子化合物，并通过旋转圆盘电极伏安法测定了它们的氧化电位。发现氧化电位低于具有苯基代替吡啶基的相应化合物的氧化电位。吡啶基与杂原子的动态配位稳定了阳离子自由基中间体，似乎是促进电子转移的原因。分子内辅助的量级随着母体化合物氧化电位的增加而增加。这种趋势可以用吡啶氮的非键合 p 轨道和母体杂原子化合物的 HOMO 之间的能量匹配来解释。
• Aryloxymethyl derivatives of nitrogenous heterocyclic methanols and ethers thereof having cardiovascular activity
  申请人：A.H. ROBINS COMPANY, INCORPORATED

  公开号：EP0279707A2

  公开（公告）日：1988-08-24

  Novel heterocyclicmethanols are disclosed having the formula: wherein Z is pyrrolidinyl, piperidinyl, homopiperidinyl or pyridinyl;     R¹ is hydrogen, loweralkyl or carbethoxymethyl;     R² is hydrogen, loweralkyl or cycloalkyl, phenyl or phenyl-loweralkyl;     R³ is 1 or 2-naphthalenyl, 2,3-dihydroinden-4 or 5-yl, phenyl or phenyl substituted by loweralkyl, loweralkoxy, halogen, trifluoromethyl, phenyl, methylenedioxy, nitro, amino, loweralkylamino, diloweralkylamino, loweracylamino;     the 1-position of 2-pyrrolidinyl, 2-piperidinyl or 2-homopiperidinyl may be substituted by an R⁴ loweralkyl group, or R¹ may form methylene or -CH₂-C(O)- bridges with R⁴;     the pharmaceutically acceptable salts and diastereomers thereof, which compounds have antiarrhythmic and/or hypotensive activity in animals.

  公开了具有以下式子的新型杂环甲醇： 其中 Z 是吡咯烷基、哌啶基、均哌啶基或吡啶基； R¹ 是氢、低级烷基或碳氧甲基； R² 是氢、低级烷基或环烷基、苯基或苯基-低级烷基； R³ 是 1 或 2-萘基、2,3-二氢茚-4 或 5-基、苯基或被低级烷基、低级烷氧基、卤素、三氟甲基、苯基、亚甲基二氧基、硝基、氨基、低级烷基氨基、稀释低级烷基氨基、低级酰基氨基取代的苯基； 2-吡咯烷基、2-哌啶基或 2-高哌啶基的 1-位可被 R⁴ 低烷基取代，或 R¹ 可与 R⁴ 形成亚甲基或-CH₂-C(O)-桥； 其药学上可接受的盐和非对映异构体，这些化合物在动物体内具有抗心律失常和/或降血压活性。